BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Pleasance E, Titmuss E, Williamson L, Kwan H, Culibrk L, Zhao EY, Dixon K, Fan K, Bowlby R, Jones MR, Shen Y, Grewal JK, Ashkani J, Wee K, Grisdale CJ, Thibodeau ML, Bozoky Z, Pearson H, Majounie E, Vira T, Shenwai R, Mungall KL, Chuah E, Davies A, Warren M, Reisle C, Bonakdar M, Taylor GA, Csizmok V, Chan SK, Zong Z, Bilobram S, Muhammadzadeh A, D’souza D, Corbett RD, Macmillan D, Carreira M, Choo C, Bleile D, Sadeghi S, Zhang W, Wong T, Cheng D, Brown SD, Holt RA, Moore RA, Mungall AJ, Zhao Y, Nelson J, Fok A, Ma Y, Lee MKC, Lavoie J, Mendis S, Karasinska JM, Deol B, Fisic A, Schaeffer DF, Yip S, Schrader K, Regier DA, Weymann D, Chia S, Gelmon K, Tinker A, Sun S, Lim H, Renouf DJ, Laskin J, Jones SJM, Marra MA. Pan-cancer analysis of advanced patient tumors reveals interactions between therapy and genomic landscapes. Nat Cancer 2020;1:452-68. [DOI: 10.1038/s43018-020-0050-6] [Cited by in Crossref: 24] [Cited by in F6Publishing: 5] [Article Influence: 12.0] [Reference Citation Analysis]
Number Citing Articles
1 Martínez-jiménez F, Muiños F, Sentís I, Deu-pons J, Reyes-salazar I, Arnedo-pac C, Mularoni L, Pich O, Bonet J, Kranas H, Gonzalez-perez A, Lopez-bigas N. A compendium of mutational cancer driver genes. Nat Rev Cancer 2020;20:555-72. [DOI: 10.1038/s41568-020-0290-x] [Cited by in Crossref: 94] [Cited by in F6Publishing: 75] [Article Influence: 47.0] [Reference Citation Analysis]
2 Rajan A, Sahu NK. Review on magnetic nanoparticle-mediated hyperthermia for cancer therapy. J Nanopart Res 2020;22. [DOI: 10.1007/s11051-020-05045-9] [Cited by in Crossref: 11] [Cited by in F6Publishing: 3] [Article Influence: 5.5] [Reference Citation Analysis]
3 Shen E, Van Swearingen AED, Price MJ, Bulsara K, Verhaak RGW, Baëta C, Painter BD, Reitman ZJ, Salama AKS, Clarke JM, Anders CK, Fecci PE, Goodwin CR, Walsh KM. A Need for More Molecular Profiling in Brain Metastases. Front Oncol 2022;11:785064. [DOI: 10.3389/fonc.2021.785064] [Reference Citation Analysis]
4 Jäger N. Bioinformatics workflows for clinical applications in precision oncology. Semin Cancer Biol 2021:S1044-579X(20)30279-0. [PMID: 33476720 DOI: 10.1016/j.semcancer.2020.12.020] [Reference Citation Analysis]
5 Williamson LM, Rive CM, Di Francesco D, Titmuss E, Chun HE, Brown SD, Milne K, Pleasance E, Lee AF, Yip S, Rosenbaum DG, Hasselblatt M, Johann PD, Kool M, Harvey M, Dix D, Renouf DJ, Holt RA, Nelson BH, Hirst M, Jones SJM, Laskin J, Rassekh SR, Deyell RJ, Marra MA. Clinical response to nivolumab in an INI1-deficient pediatric chordoma correlates with immunogenic recognition of brachyury. npj Precis Onc 2021;5. [DOI: 10.1038/s41698-021-00238-4] [Reference Citation Analysis]
6 Donoghue MTA, Schram AM, Hyman DM, Taylor BS. Discovery through clinical sequencing in oncology. Nat Cancer 2020;1:774-83. [DOI: 10.1038/s43018-020-0100-0] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
7 Lee JS, Nair NU, Dinstag G, Chapman L, Chung Y, Wang K, Sinha S, Cha H, Kim D, Schperberg AV, Srinivasan A, Lazar V, Rubin E, Hwang S, Berger R, Beker T, Ronai Z, Hannenhalli S, Gilbert MR, Kurzrock R, Lee SH, Aldape K, Ruppin E. Synthetic lethality-mediated precision oncology via the tumor transcriptome. Cell 2021;184:2487-2502.e13. [PMID: 33857424 DOI: 10.1016/j.cell.2021.03.030] [Cited by in F6Publishing: 1] [Reference Citation Analysis]